Humana (NYSE:HUM) Upgraded by Leerink Partners to Outperform Rating

Posted by Brenda Bartman on Jul 30th, 2026

Humana (NYSE:HUM – Get Free Report) was upgraded by stock analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a $513.00 target price on the insurance provider’s stock. Leerink Partners’ target price points to a potential upside of 40.21% from the company’s previous close.

HUM has been the subject of several other reports. Zacks Research upgraded Humana from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. increased their price target on Humana from $214.00 to $316.00 and gave the company a “neutral” rating in a research note on Monday, June 8th. Bank of America raised Humana from a “neutral” rating to a “buy” rating and set a $500.00 price target for the company in a report on Wednesday. Raymond James Financial lowered shares of Humana from an “outperform” rating to a “market perform” rating in a research report on Thursday. Finally, Needham & Company LLC started coverage on shares of Humana in a research note on Wednesday, May 20th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $355.87.

Check Out Our Latest Analysis on HUM

Humana Stock Down 5.9%

Shares of HUM stock opened at $365.89 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The firm’s 50-day moving average is $368.38 and its 200-day moving average is $267.06. The stock has a market cap of $43.93 billion, a price-to-earnings ratio of 39.13, a PEG ratio of 2.12 and a beta of 0.71. Humana has a 52-week low of $163.11 and a 52-week high of $428.88.

Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts’ consensus estimates of $7.26 by $0.35. The business had revenue of $40.89 billion during the quarter, compared to analysts’ expectations of $40.57 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.Humana’s quarterly revenue was up 26.2% on a year-over-year basis. During the same quarter last year, the company posted $6.27 earnings per share. Sell-side analysts predict that Humana will post 9.46 EPS for the current year.

Institutional Trading of Humana

Several institutional investors have recently added to or reduced their stakes in the company. Montag A & Associates Inc. grew its holdings in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana in the fourth quarter valued at about $27,000. Reflection Asset Management acquired a new position in shares of Humana in the fourth quarter valued at about $29,000. Finally, Bogart Wealth LLC increased its position in Humana by 192.0% during the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after acquiring an additional 48 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

Positive Sentiment: Humana reported second-quarter adjusted EPS of $7.61, exceeding the $7.26 analyst consensus, while revenue reached approximately $40.9 billion, above expectations and up 26.2% year over year. Medical costs were broadly in line with management’s expectations, with an insurance benefit ratio of 91.2%. Humana tops quarterly estimates
Positive Sentiment: Membership growth and operating expansion remained encouraging: Humana affirmed roughly 25% growth in individual Medicare Advantage membership for 2026, while CenterWell Senior Primary Care patients increased 27% year to date. Management also highlighted plans for margin improvement and strategic exits from less attractive Medicare Advantage markets. Humana Q2 earnings call highlights
Positive Sentiment: Bank of America upgraded HUM from “neutral” to “buy” and assigned a $500 price target, signaling confidence that Humana’s recovery and Medicare Advantage profitability can improve over time.
Neutral Sentiment: Humana maintained its full-year 2026 adjusted EPS outlook of at least $9.00 and affirmed its insurance benefit-ratio guidance. However, the lack of an upward revision disappointed investors after the quarterly beat. Humana reports second-quarter results
Negative Sentiment: Humana lowered its 2026 GAAP EPS outlook to at least $6.52 from at least $8.36, reflecting continued earnings headwinds from lower Medicare Advantage Star Ratings. Adjusted earnings are still expected to decline year over year, increasing concern that the recovery will take longer than anticipated. Humana cuts outlook on lower Medicare ratings
Negative Sentiment: The market reaction indicates that investors were seeking a guidance increase after the strong quarter. Instead, the unchanged adjusted outlook and reduced GAAP forecast overshadowed the earnings beat, while planned Medicare Advantage exits raise questions about near-term membership and revenue growth.

Humana Company Profile

(Get Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.